Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 16:01 ET | Source: Annexon Biosciences

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing...
May 06, 2026 08:00 ET | Source: Annexon Biosciences

Annexon to Present at the Bank of America Securities Health Care Conference 2026

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...
April 08, 2026 16:05 ET | Source: Annexon Biosciences

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...
March 30, 2026 16:01 ET | Source: Annexon Biosciences

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...
March 16, 2026 16:05 ET | Source: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...
February 24, 2026 08:00 ET | Source: Annexon Biosciences

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...
February 17, 2026 08:00 ET | Source: Annexon Biosciences

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...
January 16, 2026 17:05 ET | Source: Annexon Biosciences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...
January 12, 2026 07:00 ET | Source: Annexon Biosciences

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase...
January 08, 2026 08:00 ET | Source: Annexon Biosciences

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08,...